Entero Healthcare Solutions Limited

BSE: ENTERO544122ISIN INE010601016

Consumer Discretionary
Pharmacy Retail
BSE 1000

Share price

₹1,662.55+84.45 (+5.35%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,919.25
52W low: ₹944.00
Off 52W high: -13.38%
1M return: -1.92%
3M return: +32.17%
6M return: +37.85%
1Y return: +53.76%
20D avg volume: 10,391
50 DMA: ₹1,694.75
200 DMA: ₹1,314.42

Key ratios Consolidated

Market cap: ₹7,243 Cr
Current price: ₹1,662.55
52W high / low: ₹1,919.25 / ₹944.00
Face value: ₹10.00
P/E: 43.16
P/B: 4.28
EPS (TTM): ₹38.52
Book value / share: ₹388.09
ROE: —
ROCE: 11.60%
Operating margin: —
Net margin: —
Debt / equity: 0.32
Net debt: ₹419.80 Cr
Interest cover: 4.30
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 73.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	1,940	1,910	1,707	1,571	1,404	1,339	1,359	1,301	1,097	1,034	992.63
	3.01	4.01	4.61	4.79	5.83	7.29	7.50	11.28	13.44	9.15	1.79
	1,944	1,914	1,711	1,576	1,410	1,346	1,366	1,312	1,110	1,043	994.42
	1,876	1,856	1,663	1,531	1,373	1,309	1,327	1,277	1,083	1,030	986.10
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	1,725	1,691	1,526	1,398	1,299	1,205	1,284	1,198	1,070	956.04	911.74
	69.42	64.76	63.98	59.21	57.56	52.02	53.39	50.07	43.57	37.94	39.88
	20.57	17.31	14.01	12.40	10.66	10.49	9.97	11.46	9.70	17.32	16.07
	12.30	14.79	9.80	9.83	8.87	8.49	8.10	7.49	6.61	7.14	5.99
	54.95	56.62	40.84	39.53	31.94	29.84	7.47	10.15	26.23	25.80	—
	67.12	57.95	48.58	44.62	36.36	37.23	39.44	34.78	27.30	13.56	8.32
	0.00	0.00	-8.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	67.12	57.95	40.40	44.62	36.36	37.23	39.44	34.78	27.30	13.56	8.32
	15.07	12.82	6.52	8.03	6.13	5.80	9.99	8.74	6.77	7.62	1.34
	52.05	45.13	33.88	36.60	30.23	31.42	29.45	26.03	20.53	21.18	6.98
	8.77	6.44	6.35	7.26	6.39	5.91	5.85	5.43	4.62	5.73	1.91
Key metrics
	99.99	90.05	64.21	66.85	55.89	56.21	57.51	53.73	43.61	38.02	30.38
	5.20%	4.70%	3.80%	4.30%	4.00%	4.20%	4.20%	4.10%	4.00%	3.70%	3.10%
	2.70%	2.40%	2.00%	2.30%	2.20%	2.30%	2.20%	2.00%	1.90%	2.00%	0.70%
	—	3.70%	—	3.00%	—	2.60%	—	—	—	—	—
	38.20%	42.60%	25.60%	20.80%	28.00%	29.50%	36.90%	—	—	—	—
	72.20%	43.60%	15.00%	40.60%	47.20%	48.30%	321.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	7,128	6,591	5,096	3,922
	16.42	19.24	39.51	14.41
	7,144	6,610	5,135	3,937
	6,926	6,423	4,997	3,901
	0.00	0.00	0.00	—
	6,341	5,915	4,756	3,628
	257.37	245.50	199.04	151.15
	64.29	54.38	41.62	65.68
	46.72	43.29	30.69	25.02
	191.94	168.93	115.72	88.97
	218.27	187.51	138.74	35.55
	-8.18	-8.18	0.00	0.00
	210.09	179.34	138.74	35.55
	42.44	33.50	31.30	4.24
	167.66	145.84	107.43	39.80
	28.82	26.44	21.80	10.81
Key metrics
	321.10	277.01	211.05	126.25
	4.50%	4.20%	4.10%	3.20%
	2.35%	2.20%	2.10%	1.00%
	—	11.60%	9.70%	—
	31.94%	29.30%	29.90%	—
	43.14%	35.80%	169.90%	—
	—	28.66	-88.17	—
	—	0.66	-0.72	—
	—	0.32	0.17	—
	—	419.80	69.53	—
	—	73.5	78.3	—
Balance sheet
	—	3,600	2,703	—
	—	2,503	2,076	—
	—	146.88	229.28	—
	—	1,212	830.36	—
	—	841.68	659.78	—
	—	126.58	84.28	—
	—	103.11	132.06	—
	—	725.33	397.30	—
	—	1,588	845.02	—
	—	566.68	298.81	—
	—	444.12	298.81	—
	—	122.56	0.00	—
	—	1,753	1,770	—
Cash flow
	—	96.20	-76.86	—
	—	-303.06	219.80	—
	—	123.66	-73.66	—
	—	67.54	11.31	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	83.27	78.93	106.74	83.22	79.35	72.30	101.15	112.83	122.38	106.56	76.59
	23.14	39.96	23.25	24.23	26.29	25.87	27.51	28.81	32.17	42.40	16.25
	106.41	118.89	129.99	107.45	105.64	98.18	128.66	141.65	154.56	148.96	92.84
	101.81	106.85	124.12	99.84	96.48	86.00	114.19	121.43	126.81	123.09	92.14
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	56.81	49.53	71.33	61.30	95.91	67.18	128.77	100.11	127.33	98.08	74.34
	12.29	14.43	15.13	14.33	13.98	10.87	12.04	12.95	11.49	12.99	14.95
	5.74	2.60	0.70	0.71	0.59	0.34	0.37	0.39	0.41	5.61	4.73
	3.11	2.78	2.80	3.32	2.82	2.16	2.19	2.13	2.17	1.73	2.32
	7.75	12.19	7.49	10.70	8.99	5.83	1.46	1.36	8.20	9.06	7.24
	4.61	12.04	5.87	7.61	9.16	12.17	14.47	20.22	27.74	25.87	0.70
	0.00	0.00	-4.50	0.00	0.00	-47.08	—	—	—	—	—
	4.61	12.04	1.37	7.61	9.16	-34.91	14.47	20.22	27.74	25.87	0.70
	1.15	-1.38	0.57	1.91	2.21	-7.84	3.69	4.89	6.87	11.41	0.25
	3.46	13.42	0.81	5.70	6.96	-27.07	10.78	15.33	20.88	37.28	0.95
	0.79	3.08	0.18	1.31	1.60	-6.39	2.48	3.52	4.80	10.19	0.27
Key metrics
	13.46	17.42	4.87	11.64	12.57	-32.41	17.03	22.74	30.32	33.21	7.75
	16.20%	22.10%	4.60%	14.00%	15.80%	-44.80%	16.80%	20.20%	24.80%	31.20%	10.10%
	4.20%	17.00%	0.80%	6.80%	8.80%	-37.40%	10.70%	13.60%	17.10%	35.00%	1.20%
	—	0.80%	—	0.50%	—	-2.10%	—	—	—	—	—
	4.90%	9.20%	5.50%	-26.20%	-35.20%	-32.20%	32.10%	—	—	—	—
	-50.30%	149.60%	-92.50%	-62.80%	-66.70%	-172.60%	1,034.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	352.16	348.24	408.67	318.16
	110.58	113.72	114.37	89.92
	462.74	461.96	523.04	408.09
	432.62	427.28	449.18	383.72
	0.00	0.00	0.00	—
	238.97	278.06	423.39	288.50
	56.18	57.87	47.35	56.25
	9.75	4.61	1.52	22.32
	12.01	11.72	8.65	8.75
	38.13	39.37	29.45	26.87
	30.13	34.68	73.86	24.36
	-4.50	-4.50	-47.08	—
	25.63	30.19	26.78	24.36
	2.25	3.31	7.60	14.07
	23.39	26.88	19.18	38.44
	5.36	6.18	4.41	10.63
Key metrics
	47.39	46.52	36.95	55.43
	13.46%	13.40%	9.00%	17.40%
	6.64%	7.70%	4.70%	12.10%
	—	1.90%	1.70%	—
	-3.68%	-14.80%	28.40%	—
	289.83%	40.10%	-50.10%	—
	—	-75.27	-111.00	—
	—	-2.22	-5.68	—
	—	0.06	0.00	—
	—	50.92	-151.18	—
	—	106.9	109.6	—
Balance sheet
	—	2,158	1,804	—
	—	728.90	809.46	—
	—	56.76	151.18	—
	—	103.47	99.86	—
	—	73.33	108.98	—
	—	15.91	19.01	—
	—	17.91	25.34	—
	—	74.79	86.05	—
	—	321.87	129.93	—
	—	107.68	0.00	—
	—	15.71	0.00	—
	—	91.97	0.00	—
	—	1,683	1,650	—
Cash flow
	—	-59.72	-109.02	—
	—	-132.28	207.75	—
	—	97.58	-40.89	—
	—	15.55	1.98	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -3.68%
Profit YoY (TTM): +289.83%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +31.94%
Profit YoY (TTM): +43.14%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 52.41%

Quarter	30 Sep 2026	September 2026	June 2026	March 2026	December 2025	September 2025
Promoter %	52.41%	52.41%	52.41%	52.42%	52.42%	52.42%

Holder	Type	Holding	Previous	Change
Orbimed Asia III Mauritius Limited	Promoter	38.00%	38.00%	0.00%
Prabhat Agrawal	Promoter	9.26%	9.26%	0.00%
Prem Sethi	Promoter	5.15%	5.15%	0.00%
HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND	Public	3.19%	3.19%	0.00%
INVESCO INDIA CONTRA FUND	Public	3.19%	3.19%	0.00%
SURBHI SINGH (PRASID UNO FAMILY TRUST)	Public	3.05%	3.05%	0.00%
3P INDIA EQUITY FUND 1	Public	3.03%	3.03%	0.00%
BANK OF INDIA FLEXI CAP FUND	Public	2.40%	2.40%	0.00%
CIF III SCHEME I	Public	1.53%	1.53%	0.00%
3P INDIA EQUITY FUND 1M	Public	1.18%	1.18%	0.00%
AJAY KUMAR AGGARWAL	Public	1.01%	1.01%	0.00%
Richa Agarwal	Promoter Group	0.00%	0.00%	0.00%
Payal Agrawal	Promoter Group	0.00%	0.00%	0.00%
Vedaansh Sethi	Promoter Group	0.00%	0.00%	0.00%
Neha Agrawal	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Entero Healthcare Solutions Limited	7,243	1,662.55	43.16	11.60%	+31.94% TTM	+43.14% TTM	+53.76%
Medplus Health Services Limited	7,209	600.10	34.17	12.20%	+20.57% TTM	+8.19% TTM	-25.87%

Filings & corporate actions

Recent announcements

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.4 Nov 2026 · Company Update / General
Investor Presentation on Unaudited Financial Results for the quarter and half year ended September 30, 20264 Nov 2026 · Company Update / Investor Presentation
Grant of fresh 49,712 (Forty-Nine Thousand Seven Hundred Twelve) Employee Stock Options under the existing 'Entero Employee Stock Option Plan 2023'.4 Nov 2026 · Company Update / General
Unaudited Financial Results of the Company for the quarter and half year ended September 30, 20264 Nov 2026 · Result / Financial Results
Outcome of Board Meeting held on November 04, 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Earnings call on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 202628 Oct 2026 · Company Update / Analyst / Investor Meet
Entero Healthcare Solutions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve and take on record ....22 Oct 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 202613 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of allotment of Equity Shares upon exercise of stock options under the Entero Employee Stock Option Plan 202312 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Closure of Trading Window23 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Schedule of Analyst/Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 201522 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhi Singh - Prasid Uno Family Trust22 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Entero Healthcare Solutions Limited has informed the Exchange about General Updates12 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhi Singh Prasid Uno Family Trust26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of Schedule of Analyst/Institutional Investor meetings24 Aug 2026 · Company Update / Analyst / Investor Meet
Completion of tenure of Mr. Rajesh Shashikant Dalal24 Aug 2026 · Company Update / Change in Management
Voting Results along with copy of Scrutinizer''s Report19 Aug 2026 · AGM/EGM / AGM
Proceedings of Annual General Meeting held on Wednesday, August 19, 2026.19 Aug 2026 · AGM/EGM / AGM
Transcript of Earnings Call / Conference Call17 Aug 2026 · Company Update / Earnings Call Transcript
Recording of Earnings Call/ Conference Call on Unaudited Financial Results of the Company for the quarter ended June 30, 202610 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper publication for Unaudited Financial Results for the quarter ended June 30, 20268 Aug 2026 · Company Update / Newspaper Publication
Investor Presentation on Unaudited Financial Results for the Quarter ended June 30, 20267 Aug 2026 · Company Update / Investor Presentation
Unaudited Financial Results for the Quarter ended June 30, 2026.7 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on August 07, 20267 Aug 2026 · Board Meeting / Outcome of Board Meeting
Revised intimation of the Earnings Call on the unaudited Financial results of the Company for the quarter ended June 30, 20265 Aug 2026 · Company Update / General
Intimation of Earnings call on Unaudited Financial Results of the Company for the quarter ended June 30, 20264 Aug 2026 · Company Update / Analyst / Investor Meet
Incorporation of step-down subsidiary, Qurovia Lifesciences Private Limited31 Jul 2026 · Company Update / Acquisition
Updated Annual Report of the Company for the financial year 2025-2630 Jul 2026 · Company Update / General
Entero Healthcare Solutions Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve the Unaudited Standalone ....28 Jul 2026 · Board Meeting / Board Meeting
Newspaper Advertisement - Post dispatch of Notice of the 8th Annual General Meeting through Video Conferencing / Other Audio-Visual Means28 Jul 2026 · Company Update / Newspaper Publication
Annual Report for the financial year 2025-26 along with the Notice convening the 8th Annual General Meeting27 Jul 2026 · Company Update / General
Intimation regarding dispatch of letters to those Shareholders whose email addresses are not registered with Company/ Registrar and Share Transfer Agent/Depository Participant(s).27 Jul 2026 · Company Update / General
Business Responsibility and Sustainability Report for the Financial Year 2025-2627 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year 2025-2627 Jul 2026 · Others / Reg. 34 (1) Annual Report
The 8th Annual General Meeting of the Members of Entero Healthcare Solutions Limited is scheduled to be held on Wednesday, August 19, 2026, at 12:30 p.m. (IST) through Video Conferencing/Other ....27 Jul 2026 · AGM/EGM / AGM
News paper advertisement - 8th Annual General Meeting through Video conferencing / Other Audio - Visual Means (VC/OAVM) facility.23 Jul 2026 · Company Update / Newspaper Publication
Cessation of Mr. Rajesh Shashikant Dalal as Non- Executive Independent Director of the company w.e.f. August 24, 2026.13 Jul 2026 · Company Update / Cessation
Cessation of Mr. Rajesh Shashikant Dalal as Non- Executive Independent Director of the company w.e.f. August 24, 2026.13 Jul 2026 · Company Update / Change in Management
Certificate u/r 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 20266 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Revision in tenure of re-appointment of Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Directors of the Company.26 Jun 2026 · Company Update / Change in Management

Board meetings

4 Nov 2026 Board Meeting - Financial Results
7 Aug 2026 Board Meeting - Financial Results